Technical Solutions to Ensure Safe Yttrium-90 Radioembolization in Patients With Initial Extrahepatic Deposition of 99mTechnetium–Albumin Macroaggregates by Barentsz, M. W. et al.
TECHNICAL NOTE
Technical Solutions to Ensure Safe Yttrium-90 Radioembolization
in Patients With Initial Extrahepatic Deposition
of
99mTechnetium–Albumin Macroaggregates
M. W. Barentsz • M. A. D. Vente • M. G. E. H. Lam • M. L. J. Smits •
J. F. W. Nijsen • B. A. Seinstra • C. E. N. M. Rosenbaum • H. M. Verkooijen •
B. A. Zonnenberg • M. A. A. J. Van den Bosch
Received: 27 October 2010/Accepted: 3 December 2010/Published online: 30 December 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Purpose To evaluate the incidence of extrahepatic
deposition of technetium-99m–labeled albumin macroag-
gregates (
99mTc-MAA) after pretreatment angiography,
before yttrium-90 radioembolizaton (
90Y-RE), and to
report on technical solutions that can be used to ensure safe
delivery of
90Y-microspheres in patients with initial
extrahepatic deposition.
Materials and Methods A retrospective analysis of 26
patients with primary and secondary liver malignancies,
who were scheduled for treatment with
90Y-RE in our
institution in 2009, was performed. The angiograms and
single-photon emission computed tomography images of
all patients were reviewed by an interventional radiologist
and a nuclear medicine physician, respectively, to identify
and localize extrahepatic deposition of
99mTc-MAA when
present. Subsequently, the technical solutions were used to
successfully perform
90Y-RE in these patients were eval-
uated and described.
Results Extrahepatic deposition of
99mTc-MAA was
observedin8of26patients(31%).In7of8patients,asecond
pretreatment angiography was performedto detect the cause
of extrahepatic deposition. The technical solutions to enable
safe
90Y microspheres delivery included more distal place-
mentofthemicrocatheterintheproper/righthepaticarteryin
4 of 7 (57%) patients; (super)selective catheterization of
multiple segmental branches in 2 of 7 (29%); and additional
coiling of a newly detected branch in the remaining patient
(14%). This was conﬁrmed by a second MAA procedure.
90Y-REwaseventuallyperformedin25of26(96%)patients.
Noprocedure-relatedcomplications(\30 days)wereobserved.
Conclusion Extrahepatic deposition of
99mTc-MAA after
pretreatment angiography did occur in 8 of 26 (31%)
patients. The technical solutions as presented allowed safe
90Y-RE delivery in 25 of 26 (96%) patients.
Keywords Yttrium-90  Radioembolization 
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Introduction
Intra-arterial yttrium-90 radioembolization (
90Y-RE) is
increasingly used for treatment of patients with unresec-
table primary and secondary liver malignancies [1, 2]. For
effective targeting of these tumors,
90Y microspheres are
injected into the hepatic artery. This can be performed by
(1) placement of a catheter into the proper hepatic artery or
into each of the right (RHA) and left hepatic arteries (LHA)
separately in the same session (whole-liver treatment) or
(2) placement of catheter into each of the RHA and LHA
sequentially with an interval of 4 weeks between place-
ments (lobar treatment) [3]. Before
90Y-RE, visceral
angiography is performed for several reasons: (1) to min-
utely map out the vascular anatomy of the liver; (2) to
visualize extrahepatic vessels branching of the hepatic
artery, such as the gastroduodenal artery (GDA) and the
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these extrahepatic vessels [4]. Coil embolization is per-
formed to minimize the risk of extrahepatic deposition of
90Y microspheres during treatment. Extrahepatic deposi-
tion of
90Y microspheres may cause serious complications,
including gastrointestinal ulceration and bleeding, gastritis,
duodenitis, and pancreatitis [3, 5–8].
To determine that all necessary branches are coiled and
to assess the risk of extrahepatic deposition of
90Y micro-
spheres, a test dose of technetium-99 m–labelled albumin
macroaggregates (
99mTc-MAA) is injected. Subsequently,
single-photon emission computed tomography (SPECT) is
performed to detect potential deposition in extrahepatic
organs as well as to evaluate
99mTc-MAA distribution in
the liver. Planar nuclear imaging is used to calculate the
lung–shunt fraction [3, 5, 6]. Gastrointestinal deposition of
99mTc-MAA is an absolute contraindication for
90Y-RE
because of the previously mentioned complications [9–12].
In the literature, it has not been reported in what per-
centage of patients extrahepatic deposition of
99mTc-MAA
is observed during pretreatment angiography nor how to
proceed to
90Y-RE when extrahepatic deposition is present
after angiographic workup, including coil embolization of
extrahepatic vessels. No previous studies have described if
a second pretreatment angiogram is indicated to detect the
cause of extrahepatic deposition. Therefore, the aim of this
study was to evaluate the incidence of extrahepatic depo-
sition of
99mTc-MAA after pretreatment angiography in
patients with primary and secondary liver tumors and to
report technical solutions that can be used to ensure safe
delivery of
90Y-microspheres in these patients.
Materials and Methods
Study Design and Patient Selection
The records of 26 patients who were referred to our insti-
tution for whole-liver
90Y-RE treatment of either primary
or secondary liver malignancies were retrospectively ana-
lyzed. In all patients, resin-based microspheres (SIR-
Spheres; SIRTeX Medical Ltd., Sydney, NSW, Australia)
were used for
90Y-RE. All patients had extensive malignant
liver disease, were not eligible for surgical resection, had
minor or no extrahepatic disease, and had an acceptable
liver performance status [13]. All patients had either pro-
gressive disease after ﬁrst- or second-line chemotherapy
and/or had experienced serious side effects from chemo-
therapy. Clinical data and angiographic ﬁndings were
compiled from the patients’ medical records, and the
angiographic images were retrieved from the picture
archiving and communication system and re-evaluated.
Procedure
Preangiographic imaging was performed with either com-
puted tomography (CT) or magnetic resonance imaging
(MRI) of the liver. If a patient underwent a CT scan, this
was preferably a three-phase scan (arterial, portal, and
equilibrium phases).
90Y-RE was preceded by pretreatment
angiography to assess the individual vascular anatomy.
Angiography was performed through a femoral artery
approach using standard 5F catheters for catheterization of
the celiac axis and the superior mesenteric artery (SMA).
Subsequently, a coaxial 2.7F Progreat catheter (Terumo,
Leuven, Belgium), including a 0.018-inch guidewire, was
used for selective catheterization. Catheterization of the
SMA, celiac axis, common hepatic artery, proper hepatic
artery, left and RHA was performed in all patients.
Extrahepatic arteries branching off the common or proper
hepatic artery, such as the GDA, the gastric arteries, and
the pancreaticoduodenal branches, were actively searched
for and/or identiﬁed. A power injector was used for all
hepatic angiograms. In general, the ﬂow rate was 5 cc
contrast/s, and the total volume of contrast administered
was 15 cc. Extrahepatic arteries branching off the common
or proper hepatic artery were occluded with coil emboli-
zation. If these vessels were no longer patent on angiog-
raphy, approximately 150 MBq
99mTc-MAA was injected
through the microcatheter, with the tip of the catheter in the
proper hepatic artery (whole liver treatment) or in the
RHA/LHA (lobar treatment). Subsequently, to assess lung
shunting and to detect potential extrahepatic deposition of
99mTc-MAA, both planar imaging and SPECT was per-
formed. The time interval between
99mTc-MAA infusion
and SPECT scan was\30 minutes to prevent accumulation
of free technetium. Fusion of the nuclear images with the
pretreatment CT images was performed to identify the
distribution of
99mTc-MAA. If the distribution was dem-
onstrated to be conﬁned to the liver and liver uptake was
satisfactory, patients were readmitted within 2 weeks for
90Y-RE. During
90Y-RE treatment, the injection position of
the catheter tip was identical to the tip position during the
99mTc-MAA infusion. The
90Y microspheres were injected
either into both lobes in one session or into the RHA and
the LHA sequentially with an interval of 4 weeks. If the
SPECT images showed extrahepatic deposition, a second
pretreatment angiography was performed to identify the
branch(es) presumably accountable for the extrahepatic
deposition.
Data Extraction
The angiograms and
99mTc-MAA SPECT images coregis-
tered to the pretreatment CT images of all 26 patients were
re-evaluated by an interventional radiologist and a nuclear
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Primary outcome variables were as follows: (1) assessment
of individual vascular anatomy, (2) registration of the
occluded extrahepatic branches, (3) assessment of extra-
hepatic deposition of
99mTc-MAA according to location,
and (4) whether
90Y-RE was performed bilobar, unilobar,
superselective, or withheld. Based on these data, the
strategy used to proceed in patients with initial extrahepatic
99mTc-MAA deposition was determined.
Results
Twenty-six patients (16 men and 10 women, mean age
59 years) with liver-dominant malignant disease underwent
pretreatment angiography to determine whether they were
eligible for
90Y-RE. Demographics and baseline charac-
teristics are listed in Table 1.
Eight of 26 (31%) patients showed extrahepatic
99mTc-
MAA accumulation after pretreatment angiography. In 7 of
8 patients, extrahepatic deposition was observed in the
duodenum and/or pancreas and in 1 of 8 patients in the
gastric wall.
In seven of eight patients, a second angiography was
performed to detect branches accountable for the extrahe-
patic deposition of
99mTc-MAA. In one patient, this was not
performed because the patient was not eligible for
90Y-RE
because there were several small extrahepatic vessels orig-
inating from the proper hepatic artery that were not acces-
sible with a microcatheter. The technical solutions to enable
safe
90Y microspheres delivery are listed in Table 2.T o
summarize,thesesolutionsincludedamoredistalplacement
of the microcatheter in the proper or RHA in four of seven
patients (57%). In two of seven (29%) patients, superse-
lective catheterization of multiple segmental branches was
performed. Finally, additional coiling of an initially unde-
tected patent vessel arising from the proper hepatic artery
was performed in one of seven patients (14%). Figure 1
shows an example of this approach.
In these seven patients, no extrahepatic
99mTc-MAA
deposition was observed on SPECT images after the sec-
ond pretreatment angiography and injection of
99mTc-
MAA. During
90Y-RE treatment, the injection position of
the catheter tip was identical to the tip position during
99mTc-MAA infusion. In the total group of 26 patients who
were eligible for
90Y-RE and underwent pretreatment
angiography, 25 were ﬁnally treated with
90Y (96%). Of all
treated patients, 5 of 25 patients reported fatigue, and 2 of
25 patients reported self-limiting abdominal pain. No
directly procedure-related complications (\30 days) were
observed.
Discussion
This study shows that a signiﬁcant percentage of patients [8
of 26 (31%)] who were scheduled for whole-liver
90Y-RE
and who underwent pretreatment angiography and
99mTc-
MAA injection presented with unforeseen extrahepatic
deposition on the SPECT images. In 7 of 8 patients diag-
nosed with extrahepatic deposition, an additional pretreat-
ment angiography was performed to assess the probable
cause of extrahepatic deposition. In all seven patients, the
cause for extrahepatic deposition was identiﬁed.
Intra-arterial radioembolization with
90Y microspheres
is increasingly used in clinical practise, and its therapeutic
effect is subject to evaluation in several ongoing phase II
and III clinical trials. To our knowledge, no previous
studies have reported the incidence of extrahepatic depo-
sition of
99mTc-MAA after pretreatment angiography. The
technical solutions that we used in our patients to solve the
problem of extrahepatic deposition included more distal
positioning of the catheter (n = 4), superselective cathe-
terization of multiple segmental branches (n = 2), and
additional coiling of a patent vessel arising from the proper
Table 1 Baseline patient characteristics
Characteristics N %
No. of patients 26 100
Age, median (year) 59 ± 6.6 NA
Gender
Female 10 38
Male 16 62
Tumor type
Colorectal cancer metastases 9 35
Neuroendocrine cancer metastases 5 19
Hepatocellular carcinoma 4 15
Cholangiocarcinoma 3 11
Esophageal cancer metastases 2 8
Pancreatic cancer metastases 1 4
Ocular melanoma metastases 1 4
Unknown primary (ACUP) 1 4
Tumor treatment
Bilobar 14 54
Right unilobar 11 42
Left unilobar 0 0
No treatment 1 4
Vascular anatomy
Normal 19 73
Right hepatic origin from SMA 5 19
Other 2 8
NA not applicable, ACUP adenocarcinoma of unknown primary
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123hepatic artery (n = 1). Absence of extrahepatic deposition
of
99mTc-MAA was conﬁrmed in all seven patients with a
second SPECT scan. As a consequence, 25 of 26 patients
underwent whole-liver
90Y-RE.
Parallel to our ﬁndings, different groups have advocated
90Y-RE administered in a ‘‘bilobar lobar’’ fashion to avoid
the high incidence of extrahepatic deposition in patients
scheduled for whole-liver
90Y-RE from the proper hepatic
artery [3]. This approach of treating the whole liver of a
patient in one session is also recommended with regard to
cost-effectiveness. In this manner, fewer angiographic
procedures have to be performed, and only one dose of
90Y
has to be ordered.
More recently, it has been advised to use cone-beam CT
during pretreatment angiography to facilitate proper cath-
eter position for treatment [14]. If during the pretreatment
angiography, probable deposition outside the liver occurs,
cone-beam CT may provide guidance in determining which
speciﬁc arterial branch perfuses a particular organ. This
provides the opportunity to identify, and subsequently coil,
branches that may otherwise be accountable for extrahe-
patic deposition and therefore decrease the likelihood of
positive
99mTc-MAA SPECT. Becker et al. [15] advocated
the use of cone-beam CT for this reason, which may add
decisive information in patients scheduled for
90Y-RE and
can have an impact on the procedure itself.
Table 2 Technical solutions for eight cases of extrahepatic
99mTc-MAA deposition
Patient
no.
Diagnosis Vascular
anatomy
Coiled
arteries
Injection
site
Site of
extrahepatic
deposition
Cause Solution
1 HCC Normal GDA RHA Duodenum Suboptimal coiling
GDA with proximal
branch
Selective catheterization: more
distal in RHA (lobar)
2 Liver metastasis of
neuroendocrine
pancreatic tumor
Right-
hepatic
artery
originating
from SMA:
2 sessions
GDA RHA Duodenum/
head of
pancreas
Injection through
glide-catheter, no
microcatheter;
injection too
proximal?
New
99mTC-MAA injection with
microcatheter to bifurcation
right and median hepatic
LHA None
3 CRCLMs ?
left-sided
hemihepatectomy
Trifurcation
of the
proper
hepatic
artery
GDA Proper
hepatic
artery
Head of
pancreas
From proper hepatic
three vessels: no
extra coiling
performed
New
99mTC-MAA injection with
selective catheterization in
three segmental branches (3
injections)
4 CRCLMs ?
left-sided
hemihepatectomy
Normal GDA RHA Duodenum/
head of
pancreas
Small branch to
duodenum: too
small to coil
New
99mTC-MAA injection:
distal from branch
5 CRCLMs Normal GDA and
right
gastric
artery
Two
sessions:
small
branch to
duodenum
RHA Duodenum/
head of
pancreas
Small branch to
duodenum
(accountable for
deposition)
Coiling duodenal branch
LHA
6 ACUP Normal GDA and
right
gastric
artery
Proper
hepatic
artery
Duodenum Small branch to
duodenum: too
small to coil
New
99mTC-MAA injection with
selective catheterization in two
phases: no extra hepatic
deposition in either
7 HCC Normal GDA RHA Head of
pancreas
Small branch to head
of pancreas: too
small to coil
New
99mTC-MAA injection:
more distal from branch
8 HCC Normal,
numerous
side
branches
GDA,
cystic
artery, &
duodenal
branch
Proper
hepatic
artery
Gallbladder/
gastric
wall
Numerous side
branches
No
90Y-RE possible: TACE
CRCLMs colorectal carcinoma liver metastasis, ACUP adenocarcinoma of unknown primary
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an altered vascular anatomy in patients who were previ-
ously treated with partial hepatic resection. Two of 26
patients in our study underwent hemihepatectomy, and
both patients had deposition of
99mTc-MAA outside the
liver. In these 2 patients, we observed a vascular anatomy
with numerous neovascular branches, very small in diam-
eter, that presumably had been formed as a consequence of
the liver surgery. No literature could be found to support
this assumption. It has been reported that after liver sur-
gery, due to inﬂammatory response, neovascularization of
the vascular bed is stimulated [16]. Animal studies in mice
have shown that microvessel density increases in the liver
remnant after hepatectomy in 70% of the operated mice
[17]. We therefore emphasize that extra attention should be
given to the vascular anatomy in patients who have
undergone liver surgery, for whom superselective
90Y-RE
may be the strategy of ﬁrst choice.
To visualize aberrant vessels coming of branches of the
hepatic artery, we also recommend the use of contrast
injection with a power injector. For images of (vessels
branching from) from the proper hepatic artery, we used a
ﬂow rate of 5 cc/s and a total dose of 15 cc. For segmental
branches, we switched to a ﬂow rate of 2 to 3 cc/s and a
total dose of 10–12 cc.
It is imperative to ensure that possible extrahepatic
deposited
99mTc-MAA indeed is located outside the liver. In
our center, we had to use SPECT/CT-fusion images to
determine extrahepatic deposition of
99mTc-MAA. How-
ever, the SPECT and CT images were not recorded simul-
taneously, so both are subject to various inﬂuences. Gastric
ﬁlling, for example, can differ during both procedures and
may inﬂuence the positioning of abdominal organs, espe-
cially in oral contrast-enhanced CT imaging. Correct fusion
of the SPECT and CT images may therefore be difﬁcult or
even impossible, and deposition of
99mTc-MAA may be
falsely concluded to be present. It is important to perform
pretreatmentthree-phaseCTandSPECTwithinareasonable
time frame. A dedicated SPECT/CT system, i.e., a gamma
camera combined with an integrated low-dose computed
tomograph, could increase both sensitivity and speciﬁcity in
detecting extrahepatic
99mTc-MAA accumulation [18].
One of the limitations of this study is the short-term
follow-up of 30 days. Although we believe that all proce-
dure-related complications may become manifest within
this time frame, gastrointestinal ulcers with a delayed pre-
sentation may potentially have been missed. Furthermore,
possible gain in terms of decreased treatment time and
decreased procedure-related costs may have been offset by
the relative high number (31%) of readmissions fora second
99mTc-MAA procedure. This study was not designed to
compare different treatment strategies, i.e., proximal whole-
liver treatment versus selective whole-liver treatment, but
this may be an interesting issue for further research.
Fig. 1 A Initial angiogram of the common hepatic artery after coiling
of the GDA. B SPECT/CT fusion images of the liver, after
99mTC-
MAA injection, suggesting extrahepatic uptake (indicated by the
arrow). C Second angiogram with the microcatheter in the branch
causing extrahepatic deposition in duodenum/head of pancreas on
SPECT. D Angiogram with injection of
99Tc-MAA after subsequent
coiling of the small pancreaticoduodenal branch
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123In conclusion, extrahepatic deposition of
99mTc-MAA
does occur in some patients undergoing angiographic
workup for
90Y-RE. Our data suggest (1) that these patients
should receive one additional angiographic procedure to
detect previously undetected patent extrahepatic vessels
arising from the hepatic artery and (2) that the possibility of
a more selective (e.g., distal) placement of the catheter for
injection of
99mTc-MAA should be evaluated. By applying
these strategies,
90Y-RE can be performed safely. In our
case series, no signs were observed related to extrahepatic
radioactivity in any of our patients after administration of
90Y-RE.
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